Prime Medicine (NasdaqGM:PRME) FY Conference December 02, 2025 11:15 AM ET Company ParticipantsAllan Reine - CEOModeratorThank you guys for being here. Super excited to have an old friend join us for a new fireside chat.Allan ReineYes, thank you for having us.ModeratorIt's great to have you. We all want to learn prime medicine and prime editing, but I'll let you kick things off.Allan ReineThanks, Emmer. Again, thank you for having us. Pleasure to be here in Miami, escape the weather in New York. Yeah, what ...

Core Insights - Prime Medicine, Inc. has appointed Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer to lead corporate and business development initiatives, corporate strategy, and alliance management [1][2][4] - The company aims to expand the reach of its Prime Editing technology through strategic partnerships and collaborations, which are considered a core pillar of its strategy [2][4] - Dr. Hawryluk brings nearly two decades of experience in the biotechnology industry, having previously held leadership roles at AIRNA Corporation and Gritstone bio, Inc., where he led significant financing and collaborations [2][3] Company Overview - Prime Medicine is focused on delivering a new class of one-time curative genetic therapies using its proprietary Prime Editing platform, which allows precise and efficient gene editing [5][6] - The company is advancing a diversified portfolio of investigational therapeutic programs targeting liver, lung, immunology, and oncology diseases, with plans to expand into additional genetic and immunological diseases, cancers, and infectious diseases [6][7] - Prime Editing technology has the potential to repair various genetic mutations and is designed to minimize unwanted DNA modifications, unlocking opportunities across thousands of potential indications [5][6]

Company Overview - Rubrik is valued at $15.2 billion and specializes in data security, backup, recovery, and cloud-based protection, particularly relevant in the context of increasing ransomware and data breach risks [3] - The company reported a significant increase in subscription annual recurring revenue (ARR) to over $1.25 billion, up 36% year-over-year, with cloud ARR surging 57% to $1.1 billion [2] Financial Performance - Overall revenue increased by 51% to $310 million, with subscription revenue rising by 55% [1] - Adjusted net loss narrowed to $0.03 from $0.40 in the same quarter last year, and adjusted gross margin improved to 82% from 77% [1] - Free cash flow improved to $57.5 million from a negative $32 million last year, indicating a stronger financial position [6] Market Position and Analyst Sentiment - Analysts predict Rubrik's revenue to grow by 39.2% in 2025 and 25% in 2026, reflecting confidence in the company's growth trajectory [7] - The stock is rated as a "Strong Buy" by 18 out of 21 analysts, with an average target price of $114.95, suggesting a potential upside of 49.8% [8] Investment Activity - Cathie Wood's ARK Next Generation Internet ETF purchased 66,836 shares of Rubrik for $6.6 million, increasing total investment in the company to $35 million [3][4] - Wood's investment strategy focuses on disruptive innovation and long-term growth, aligning with Rubrik's fundamentals and market trends [5][7]

Core Insights - Prime Medicine has secured up to $24 million in additional funding from the Cystic Fibrosis Foundation to accelerate the development of Prime Editors for cystic fibrosis (CF) [1][2][3] - The funding aims to enhance Prime Editing technology, which has the potential to correct a wide range of genetic mutations affecting over 93% of individuals with CF [1][2] - The initial focus will be on the G542X mutation, a prevalent CF-causing mutation with no current therapies available [2] Company Overview - Prime Medicine is a biotechnology company dedicated to developing one-time curative genetic therapies using its proprietary Prime Editing platform, which allows precise and efficient gene editing [5][6] - The company is advancing a diversified portfolio of therapeutic programs targeting liver, lung, immunology, and oncology diseases [6][7] - Prime Editing technology is designed to minimize unwanted DNA modifications while effectively repairing various genetic mutations across different tissues and organs [5] Funding Details - The CF Foundation's investment builds on an earlier agreement from January 2024 and will be provided in two tranches, with the first tranche including a $6 million equity investment [2][3] - The funding is contingent upon meeting certain scientific milestones and closing conditions [3] Disease Context - Cystic fibrosis is a serious genetic disease caused by mutations in the CFTR gene, affecting approximately 100,000 people globally, including over 40,000 in the United States [4] - Current disease-modifying therapies are not curative and may be ineffective for certain mutations, highlighting the need for innovative treatments [4]